Product Number |
OAPB00219 |
Product Page |
www.avivasysbio.com/ace2-antibody-oapb00219.html |
Name |
ACE2 Antibody (OAPB00219) |
Molecular Weight |
Predicted: 93kD Observed: 130 kD (7 N-linked glycosylation) |
Isotype |
IgG |
Conjugation |
Unconjugated |
NCBI Gene Id |
59272 |
Host |
Rabbit |
Clonality |
Polyclonal |
Concentration |
1 mg/ml |
Gene Full Name |
angiotensin converting enzyme 2 |
Alias Symbols |
ACEH;ACE-related carboxypeptidase;angiotensin I converting enzyme (peptidyl-dipeptidase A) 2;angiotensin I converting enzyme 2;angiotensin-converting enzyme 2;angiotensin-converting enzyme homolog;angiotensin-converting enzyme-related carboxypeptidase;metalloprotease MPROT15;peptidyl-dipeptidase A;truncated angiotensin converting enzyme 2. |
Product Format |
Liquid. ACE2 Antibody is supplied in PBS containing 0.02% sodium azide. |
Reference |
Donoghue et al. Circ. Res. 2000;87:1-9. Tipnis et al. J Biol. Chem. 2000;275:33238-43. Li et al. Nature 2003;426:450-4. Lu et al. The Lancet 2020 (published online). Crackower et al. Nature 2002;417:822-8. |
Description of Target |
Essential counter-regulatory carboxypeptidase of the renin-angiotensin hormone system that is a critical regulator of blood volume, systemic vascular resistance, and thus cardiovascular homeostasis (PubMed:27217402). Converts angiotensin I to angiotensin 1-9, a nine-amino acid peptide with anti-hypertrophic effects in cardiomyocytes, and angiotensin II to angiotensin 1-7, which then acts as a beneficial vasodilator and anti-proliferation agent, counterbalancing the actions of the vasoconstrictor angiotensin II (PubMed:10969042, PubMed:10924499, PubMed:11815627, PubMed:19021774, PubMed:14504186). Also removes the C-terminal residue from three other vasoactive peptides, neurotensin, kinetensin, and des-Arg bradykinin, but is not active on bradykinin (PubMed:10969042, PubMed:11815627). Also cleaves other biological peptides, such as apelins (apelin-13, [Pyr1]apelin-13, apelin-17, apelin-36), casomorphins (beta-casomorphin-7, neocasomorphin) and dynorphin A with high efficiency (PubMed:11815627, PubMed:27217402, PubMed:28293165). In addition, ACE2 C-terminus is homologous to collectrin and is responsible for the trafficking of the neutral amino acid transporter SL6A19 to the plasma membrane of gut epithelial cells via direct interaction, regulating its expression on the cell surface and its catalytic activity (PubMed:18424768, PubMed:19185582). |
Reconstitution and Storage |
2°C to 8°C |
Datasheets/Manuals |
Printable datasheet for ACE2 Antibody (OAPB00219) (OAPB00219) |
Specificity |
Anti-ACE2 has no cross response to ACE1. |
Additional Information |
Positive Control: Human Kidney, Human Spleen |
Application Info |
WB: 1-2 ug/mL IHC: 2 ug/mL IF: 10 ug/mL. Antibody validated: WB in human, mouse and rat samples; IHC in human samples; IF in human, mouse and rat samples. |
Blocking Peptide |
For anti-ACE2 antibody is Catalog # OEPB02313 |
Immunogen |
Anti-ACE2 antibody (3227) was raised against a peptide corresponding to 14 amino acids near the amino terminus of human ACE2. The immunogen is located within the first 50 amino acids of ACE2. |
Uniprot ID |
Q9BYF1 |
Protein Name |
Angiotensin-converting enzyme 2|angiotensin-converting enzyme 2 precursor [Homo sapiens] |
Protein Accession # |
https://www.ncbi.nlm.nih.gov/protein/NP_068576 |
Purification |
Affinity Purified |
Gene Symbol |
ACE2 |
Predicted Species Reactivity |
Bovine|Human|Mouse|Rat |
Application |
Enzyme-linked immunosorbent assay|Immunofluorescence|Immunohistochemistry-Paraffin|Western blot |
Predicted Homology Based on Immunogen Sequence |
Predicted species reactivity based on immunogen sequence: Bovine: (86%) |
Image 1 | Human Kidney Cells
| Figure 6 Immunofluorescence Validation of ACE2 in Human Kidney Cells
Immunofluorescent analysis of 4% paraformaldehyde-fixed human kidney cells labeling ACE2 at 10 ug/mL, followed by goat anti-rabbit IgG secondary antibody at 1/500 dilution (red).
|
|
Image 2 | Human Kidney Tissue
| Figure 5 Immunohistochemistry Validation of ACE2 in Human Kidney Tissue
Immunohistochemical analysis of paraffin-embedded human kidney tissue using anti-ACE2 antibody at 2 ug/ml. Tissue was fixed with formaldehyde and blocked with 10% serum for 1 h at RT; antigen retrieval was by heat mediation with a citrate buffer (pH6). Samples were incubated with primary antibody overnight at 4C. A goat anti-rabbit IgG H&L (HRP) at 1/250 was used as secondary. Counter stained with Hematoxylin.
|
|
Image 3 | Human Tissues
| Figure 2 Western Blot Validation in Human Tissues
Loading: 15 ug of lysates per lane.
Antibodies: ACE2 (1 ug/mL), 1h incubation at RT in 5% NFDM/TBST.
Secondary: Goat anti-rabbit IgG HRP conjugate at 1:10000 dilution.
|
|
Image 4 | Mouse Tissues
| Figure 3 Western Blot Validation in Mouse Tissues
Loading: 15 ug of lysates per lane.
Antibodies: ACE2 (2 ug/mL), 1h incubation at RT in 5% NFDM/TBST.
Secondary: Goat anti-rabbit IgG HRP conjugate at 1:10000 dilution.
|
|
Image 5 | Rat Thymus Tissue
| Figure 4 Western Blot Validation in Rat Thymus Tissue
Loading: 15 ug of lysates per lane.
Antibodies: ACE2 (2 ug/mL), 1h incubation at RT in 5% NFDM/TBST.
Secondary: Goat anti-rabbit IgG HRP conjugate at 1:10000 dilution.
|
|
Image 6 | Human Tissues
| Figure 1 Independent Antibody Validation (IAV) via Protein Expression Profile in Human Tissues (kidney, spleen testis, breast, intestine)
Loading: 15 ug of lysates per lane.
Antibodies: OAPB00213 (2 ug/mL), OAPB00214 (2 ug/mL), OAPB00219 (2 ug/mL) and beta-actin (1 ug/mL), 1h incubation at RT in 5% NFDM/TBST.
Secondary: Goat anti-rabbit IgG HRP conjugate at 1:10000 dilution. |
|